22 min listen
Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in Urothelial Bladder Cancer with Dr Ashish Kamat
Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in Urothelial Bladder Cancer with Dr Ashish Kamat
ratings:
Length:
52 minutes
Released:
Nov 5, 2020
Format:
Podcast episode
Description
Dr Ashish Kamat from the University of Texas MD Anderson Cancer Center in Houston discusses recently published and emerging research on the use of immune checkpoint inhibitors and other novel therapies for patients with urothelial bladder cancer.
CME information and select publications here (http://www.researchtopractice.com/OncologyTodayAUABladder20).
CME information and select publications here (http://www.researchtopractice.com/OncologyTodayAUABladder20).
Released:
Nov 5, 2020
Format:
Podcast episode
Titles in the series (100)
Dr Tom Lynch on Adjuvant EGFR TKIs in Lung Cancer and COVID-19 in Seattle: Dr Tom Lynch comments on the current status of oncology research and data soon to be presented from a Phase III trial evaluating the EGFR TKI osimertinib as adjuvant therapy for patients with non-small cell lung cancer and EGFR tumor mutations. by Oncology Today with Dr Neil Love